DCC-2157

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameDCC-2157

Drug Alias NameDCC-2157

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsTyrosine-protein kinase receptor RET inhibitorsVascular endothelial growth factor receptor 2 antagonists +[5]

TargetsStem cell growth factor receptorBcr-Abl tyrosine kinaseVascular endothelial growth factor receptor 2 +[5]

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesDeciphera Pharmaceuticals Llc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDeciphera Pharmaceuticals Llc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A